Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jul 28, 2026
Company Drug

Ipsen’s Somatuline Receives First Prescription in China for GEP-NETs Treatment

Fineline Cube Apr 23, 2024

French biopharmaceutical company Ipsen (EPA: IPN; OTCMKTS: IPSEY) has announced that the first prescription of...

Company

Chongqing Zhifei Biological Reports 38.3% YOY Revenue Growth in 2023 Financial Results

Fineline Cube Apr 23, 2024

Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a biopharmaceutical company based in China, has released...

Company Deals

Genrix Biopharmaceutical Partners with China Resource Medicine for Expanded Market Coverage

Fineline Cube Apr 23, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a Chinese biopharmaceutical company, has entered into a...

Company Deals

Takeda and Astellas Join Forces with Sumitomo Mitsui to Launch Drug Discovery Joint Venture

Fineline Cube Apr 23, 2024

Japanese pharmaceutical giants Takeda (NYSE: TAK) and Astellas (TSE: 4503) have joined hands with compatriot...

Company

GenScript Biotech Corporation Reports 34.2% YOY Revenue Growth in 2023 Financial Results

Fineline Cube Apr 23, 2024

China-based GenScript Biotech Corporation (HKG: 1548) has announced its financial results for 2023, reporting revenues...

Company Deals

Bristol Myers Squibb Enhances CAR-T Manufacturing with Cellares Platform, Securing Exclusive Access

Fineline Cube Apr 23, 2024

Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has secured a deal with Cellares, a...

Company

Zai Lab Ltd Appoints New Greater China CCO as Liang Yi Exits

Fineline Cube Apr 23, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the appointment of Zhu Tong as...

Policy / Regulatory

China’s NMPA Introduces 12 Measures to Strengthen Drug Operation Administration

Fineline Cube Apr 23, 2024

The National Medical Products Administration (NMPA) has issued a notification with 12 measures aimed at...

Company Deals

MSD Strikes Deal with GV20 Therapeutics to Test Anti-PD-1 Combo in Solid Tumor Therapies

Fineline Cube Apr 22, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a global healthcare leader, has entered into a...

Company Drug

Jiangsu Hengrui’s SHR-A2102 Earns FDA Fast Track Status for Urothelial Carcinoma Treatment

Fineline Cube Apr 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...

Company Drug

Hengrui Pharmaceuticals Gets Green Light from NMPA for Two Anti-Cancer Drugs

Fineline Cube Apr 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company

Bayer CEO Joins German Chancellor on China Visit, Announces New Investments

Fineline Cube Apr 22, 2024

Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a multinational pharmaceutical and life sciences company...

Company Drug

GSK’s Gepotidacin Shows Non-Inferior Efficacy in Phase III Gonorrhoea Tria

Fineline Cube Apr 22, 2024

GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK), a leading UK pharmaceutical company, last week announced positive...

Company Drug

Joincare Pharmaceutical’s TG-1000 Shows Promise in Phase III Flu Treatment Trial

Fineline Cube Apr 22, 2024

Joincare Pharmaceutical Group Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has reportedly completed the...

Company Legal / IP

Kind Pharmaceuticals Resolves Trade Secrets Dispute with Fibrogen Amid HIF-PHI Pipeline Development

Fineline Cube Apr 22, 2024

Kind Pharmaceuticals LLC, a Sino-US pharmaceutical company, along with its Chinese affiliate Hangzhou Andao Pharmaceutical...

Company Drug

Roche’s Alecensa approved by FDA as First ALK Inhibitor for Adjuvant Treatment of NSCLC

Fineline Cube Apr 22, 2024

Roche Holding AG (SWX: ROG; OTCMKTS: RHHBY), a Swiss multinational healthcare company, announced last week...

Company Drug

Takeda Scores FDA Nod for Subcutaneous Vedolizumab to Treat Inflammatory Bowel Disease

Fineline Cube Apr 22, 2024

The US Food and Drug Administration (FDA) has granted Takeda Pharmaceutical Company Limited (NYSE: TAK),...

Company Deals

CareRay Digital Medical Invests $15 Million for Stake in X-Ray Detector Maker ISID

Fineline Cube Apr 22, 2024

CareRay Digital Medical Technology Co., Ltd, a leading medical technology company based in Jiangsu, has...

Drug Medical Device Policy / Regulatory

China’s Health Authorities Investigate Alleged Price Manipulation in Pharma Procurement Tenders

Fineline Cube Apr 22, 2024

Chinese health regulators are delving into allegations of irregular pricing practices during the national volume-based...

Company Deals

Impact Therapeutics Boosts War Chest with $55.2 Million Series D+ Round for Cancer Drugs

Fineline Cube Apr 22, 2024

Impact Therapeutics, a biopharmaceutical company based in China, has reportedly secured RMB 400 million (USD...

Posts pagination

1 … 406 407 408 … 700

Recent updates

  • HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases
  • Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals
  • China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio
  • Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy
  • CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Company

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Company Medical Device

Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.